PEGylated nanoliposomes encapsulating angiogenic peptides improve perfusion defects: Radionuclide imaging-based study.

[1]  Hwan-Jeong Jeong,et al.  Improving Cerebral Blood Flow Through Liposomal Delivery of Angiogenic Peptides: Potential of 18F-FDG PET Imaging in Ischemic Stroke Treatment , 2015, The Journal of Nuclear Medicine.

[2]  Chang-Moon Lee,et al.  Peptide-loaded nanoparticles and radionuclide imaging for individualized treatment of myocardial ischemia. , 2014, Radiology.

[3]  Hwan-Jeong Jeong,et al.  Effect of Angiogenesis Induced by Consecutive Intramuscular Injections of Vascular Endothelial Growth Factor in a Hindlimb Ischemic Mouse Model , 2014, Nuclear Medicine and Molecular Imaging.

[4]  V. Bautch,et al.  Building blood vessels in development and disease , 2013, Current opinion in hematology.

[5]  P. Cullis,et al.  Liposomal drug delivery systems: from concept to clinical applications. , 2013, Advanced drug delivery reviews.

[6]  Clinton D. Protack,et al.  Toward a mouse model of hind limb ischemia to test therapeutic angiogenesis. , 2012, Journal of vascular surgery.

[7]  Xiao Lin,et al.  PEGylation for drug delivery to ischemic myocardium: pharmacokinetics and cardiac distribution of poly(ethylene glycol)s in mice with normal and ischemic myocardium. , 2012, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[8]  S. Ziyad,et al.  Molecular mechanisms of tumor angiogenesis. , 2011, Genes & cancer.

[9]  M. Martín-Martínez,et al.  Parallel solid-phase synthesis of a small library of linear and hydrocarbon-bridged analogues of VEGF(81-91): potential biological tools for studying the VEGF/VEGFR-1 interaction. , 2011, Bioorganic & medicinal chemistry.

[10]  Hua Su,et al.  Coexpression of VEGF and angiopoietin-1 promotes angiogenesis and cardiomyocyte proliferation reduces apoptosis in porcine myocardial infarction (MI) heart , 2011, Proceedings of the National Academy of Sciences.

[11]  E. Feigl,et al.  Fibroblast growth factor-2 regulates myocardial infarct repair: effects on cell proliferation, scar contraction, and ventricular function. , 2007, The American journal of pathology.

[12]  D. Stewart,et al.  Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF121 (AdVEGF121) versus maximum medical treatment , 2006, Gene Therapy.

[13]  J. Tijssen,et al.  START Trial: A Pilot Study on STimulation of ARTeriogenesis Using Subcutaneous Application of Granulocyte-Macrophage Colony-Stimulating Factor as a New Treatment for Peripheral Vascular Disease , 2005, Circulation.

[14]  H. Blau,et al.  Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis. , 2004, The Journal of clinical investigation.

[15]  Brian H Annex,et al.  A target‐mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans , 2002, Clinical pharmacology and therapeutics.

[16]  T. Henry,et al.  Pharmacological Treatment of Coronary Artery Disease With Recombinant Fibroblast Growth Factor-2: Double-Blind, Randomized, Controlled Clinical Trial , 2002, Circulation.

[17]  H. Maeda,et al.  Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[18]  D. Papahadjopoulos,et al.  Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. , 1999, Pharmacological reviews.

[19]  J. Pearlman,et al.  Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery: results of a phase I randomized, double-blind, placebo-controlled trial. , 1999, Circulation.

[20]  J. Pearlman,et al.  VEGF administration in chronic myocardial ischemia in pigs. , 1998, Cardiovascular research.

[21]  A. D. de Vos,et al.  VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 A resolution and mutational analysis of the interface. , 1998, Structure.

[22]  J. Isner,et al.  Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. , 1995, Circulation.

[23]  L. Horwitz,et al.  Time course of coronary endothelial healing after injury due to ischemia and reperfusion. , 1994, Circulation.

[24]  Kazuo Maruyama,et al.  Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes , 1990, FEBS letters.

[25]  J H Senior,et al.  Fate and behavior of liposomes in vivo: a review of controlling factors. , 1987, Critical reviews in therapeutic drug carrier systems.

[26]  C. Hunt,et al.  Liposome disposition in vivo. III. Dose and vesicle-size effects. , 1981, Biochimica et biophysica acta.